SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco is currently trending as investors monitor its resilience amid macroeconomic volatility and ongoing debates surrounding the impact of potential tariff refunds on retail pricing. The community remains focused on Costco's defensive strengths, with frequent discussions centered on its robust membership renewal rates, traffic growth, and valuation relative to the broader consumer staples sector.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics is generating significant investor interest driven by high trading volumes, active momentum in its clinical-stage pipeline, and multiple analyst endorsements from firms like Guggenheim and HC Wainwright. Community discussion is focused on the high-stakes Phase 2 LOTUS trial readout expected in 2026 and ongoing debates regarding the company's financial risk profile versus the potential upside of its immunology platform.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently a focal point for the community due to renewed institutional interest, shifting ecosystem management, and ongoing discussions regarding its quantum-resistant technology. While some traders debate the asset's long-term viability following historic price volatility, active participants are heavily focused on potential regulatory catalysts and the ongoing expansion of its real-world asset (RWA) utility.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF is capturing investor attention as they rotate toward defensive, value-oriented positions amidst broader market volatility. The community is actively debating the fund's resilience, with many investors maintaining a long-term 'buy and hold' strategy despite recent stagnant performance, while others monitor the ETF's sector diversification and dividend growth potential as a reliable hedge.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community speculates on a major upcoming partnership announcement, with many pointing to a connection with Stellar or a potential collaboration with Ripple/XRP at an upcoming industry event. Investors are actively debating the project's long-term utility in global payroll and real-world adoption, balancing high-conviction sentiment against skepticism regarding its price performance and market volatility.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include Core, Cognitive Adjacencies, and Network Software and Services. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

Arista Networks is currently trending due to intense volatility following a quarterly earnings report that featured a strong double beat on top and bottom lines but provided cautious forward revenue guidance. The community is actively debating whether the double-digit price decline is a baseless overreaction caused by market makers or a justified correction given the stock's high valuation and competitive concerns within the AI infrastructure sector.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending as investors weigh the potential impact of looming pharmaceutical tariffs, which are pushing the company to increase its U.S. manufacturing footprint. Simultaneously, the community is actively debating the company's aggressive M&A strategy, particularly its focus on expanding oncology and T-cell engager therapy pipelines, while keeping a watchful eye on patent litigation risks.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as the community debates its long-term viability, with supporters pointing to upcoming regulatory clarity like the Clarity Act and existing infrastructure partnerships, while skeptics emphasize a prolonged downward price trend and lack of active communication from project leadership.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is a primary focal point of market discourse following the FDA approval of Foundayo, its once-daily oral GLP-1 weight-loss pill, which analysts view as a major step toward expanding the obesity treatment market through improved convenience and scalability. While community discussion remains intense regarding its competitive positioning against Novo Nordisks oral offerings, the broader pharma sector is also digesting the implications of potential new pharmaceutical tariff policies and ongoing M&A activity, keeping Eli Lillys valuation and long-term growth trajectory at the center of investor focus.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is seeing significant market activity and heightened community discourse driven by persistent acquisition rumors and notable institutional volume in after-hours trading. Traders are actively debating the stock's valuation relative to its rare disease pipeline, while observing unconventional trading patterns that have fueled speculation of a potential buyout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE PR Newswire REHOVOT, Israel, March 26, 2026 REHOVOT, Israel, March 26, 2026 /PRNewswire/ -- CollPlantBiotechnologies (Nasdaq...

CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement

CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement PR Newswire REHOVOT...

CollPlant Biotechnologies Launches Redesigned Corporate Website

CollPlant Biotechnologies Launches Redesigned Corporate Website CollPlant Biotechnologies Launches Redesigned Corporate Website PR Newswire REHOVOT, Israel, March 18, 2026 REHOVOT, Israel, March 18...

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FULL YEAR 2025 FINANCIAL RESULTS

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FULL YEAR 2025 FINANCIAL RESULTS COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FULL YEAR 2025 FINANCIAL RESULTS PR Newswire REHOVOT, Israel, March 11, 2026...

CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler

CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal...

CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex

CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex PR Newswire...

CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments

CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments PR Newswire REHOVOT, Israel, Feb. 17, 2026...

COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING

COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING PR Newswire REHOVOT, Israel, Feb. 5, 2026...

<ul class="summary-bullets"><li>The workforce reduction plan is expected to impact 25% of the company’s workforce.</li><li>The company’s adjusted net loss per share in Q3 came in at $0.25, but analysts, on average, expected earnings of $0.15 per share.</li><li>The company reported revenue of $77,000 for the three months ended September.</li></ul>Shares of CollPlant Biotechnologies (CLGN) slumped 14% on Wednesday morning after the company reported third-quarter earnings below Wall Street expectations.The firm <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/collplant-biotechnologies-reports-2025-third-quarter-financial-results-and-provides-corporate-update-302626666.html">reported</a> revenue of $77,000 for the three months ended September, above the $4,000 reported in the corresponding quarter of 2024, but below an analyst estimate of $5.03 million, according to data from Fiscal AI.Adjusted net loss per share came in at $0.25, lower than the $0.33 loss reported in the corresponding quarter of 2024. Still, analysts, on average, were expecting the company to report earnings of $0.15 per share.<h2 class="st-heading-2">Cost-Cutting Efforts And Layoffs</h2>The company said it has initiated a cost-cutting and workforce-reduction plan, which is expected to result in about a 25% cut in its workforce."In 2026, CollPlant will prioritize its collaboration with AbbVie and continue advancing its own dermal filler product candidate… In parallel, we plan to actively seek a strategic partner to collaborate with us on the continued development of our novel regenerative breast implant product candidate," Collplant CEO Yehiel Tal said.CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The company's products are based on its recombinant human collagen. The company entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, in 2021."We remain highly encouraged by the additional results emerging from the preclinical studies of our commercial-size regenerative breast implants, as well as from the ongoing evaluations of our photocurable dermal filler program,” Tal added. The photocurable derma filler program is now in the final stages of preclinical testing, and the company is now preparing for the initial clinical studies, IT said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, the retail sentiment around <a href="https://stocktwits.com/symbol/CLGN">CLGN stock</a> stayed within the ‘bullish’ territory over the past 24 hours while message volume rose from ‘low’ to ‘normal’ levels.CLGN stock is down 44% this year and by about 53% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nyxoah-sa-stock-rises-pre-market-after-cms-raises-reimbursement-for-sleep-disorder-therapy/cL538b3REWB">Nyxoah SA Stock Rises Pre-Market After CMS Raises Reimbursement For Sleep Disorder Therapy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, a smartphone displays the logo of CollPlant Biotechnologies Ltd., an Israel-based regenerative and aesthetic medicine company, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

CLGN Stock Crashed 14% Today – Disappointing Earnings, Workforce Reduction Plan Draws Investor Attention

The firm reported revenue of $77,000 for the three months ended September, above the $4,000 reported in the corresponding quarter of 2024, but below an analyst estimate of $5.03 million, according to data from Fiscal AI. 

Equity

The firm reported revenue of $77,000 for the three months ended September, above the $4,000 reported in the corresponding quarter of 2024, but below an analyst estimate of $5.03 million, according to data from Fiscal AI. 


COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE...

CollPlant Biotechnologies Ltd. operates as a regenerative and aesthetic medicine company. It engages in the research, development, manufacture, and marketing of medical products for tissue repair such as bioprinting of tissues and organs, and medical aesthetics. Its products include VergenixSTR, VergenixFG, and Collink.3D. The company was founded by Oded Shoseyov in June 2004 and is headquartered in Rehovot, Israel.

CollPlant Biotechnologies Ltd - Ordinary Shares New

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

CLGN
CollPlant Biotechnologies Ltd - Ordinary Shares New

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CLGN News

CLGNCollPlant Biotechnologies Ltd - Ordinary Shares New